The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates. The ...

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

BioArctic’s partner Eisai announces update on regulatory review of lecanemab to treat early Alzheimer’s disease in EU: Stockholm Monday, February 3, 2025, 13:00 Hrs [IST] BioA ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

Delayed REM sleep may be linked to a higher risk of Alzheimer’s disease, new research found. Here's how to build a healthy sleep routine.

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...